Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;189(1):39-53.
doi: 10.1111/bjh.16377. Epub 2020 Feb 17.

Advances in knowledge of inhibitor formation in severe haemophilia A

Matthew Cormier  1 , Paul Batty  1 , Julie Tarrant  1 , David Lillicrap  1
Affiliations
Review

Advances in knowledge of inhibitor formation in severe haemophilia A

Matthew Cormier et al. Br J Haematol. 2020 Apr.

Abstract

Anti-drug antibody formation following factor VIII (FVIII) replacement therapy is the most important treatment-related complication in patients with severe haemophilia A. A significant number of these antibodies show neutralising activity against FVIII and are referred to as FVIII inhibitors. Alloimmunity to FVIII, given the absence of endogenous circulating FVIII protein, may be predictable to some extent; however, only 30% of patients develop inhibitors. Genetic and environmental risk factors have been identified, contributing to the likelihood of inhibitor development. Multiple immunological theories have been proposed which in part explain the outcomes of many epidemiological studies. Significant differences exist among replacement therapies, including the source, FVIII sequence, glycosylation, formulation components, impurities and aggregation potential, which significantly complicate interpretation of the results from these studies. In this review, we present recent advances in the understanding of the cellular mechanisms of inhibitor formation and highlight some areas of uncertainty requiring further investigation.

Keywords: factor VIII; haemophilia; immunology; inhibitor.

PubMed Disclaimer

References

    1. Aledort, L.M., Navickis, R.J. & Wilkes, M.M. (2011) Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. Journal of Thrombosis and Haemostasis, 9, 2180-2192.
    1. Arpaia, N., Campbell, C., Fan, X., Dikiy, S.,van der Veeken, J., deRoos, P., Liu, H., Cross, J.R., Pfeffer, K., Coffer, P.J. & Rudensky, A.Y. (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 504, 451-455.
    1. Azad, M.B., Konya, T., Persaud, R.R., Guttman, D.S., Chari, R.S., Field, C.J., Sears, M.R., Mandhane, P.J., Turvey, S.E., Subbarao, P., Becker, A.B., Scott, J.A. & Kozyrskyj, A.l. (2016) Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG: An International Journal of Obstetrics & Gynaecology, 123, 983-993.
    1. Bamboat, Z.M., Stableford, J.A., Plitas, G., Burt, B.M., Nguyen, H.M., Welles, A.P., Gonen, M., Young, J.W. & DeMatteo, R.P. (2009) Human liver dendritic cells promote T cell hyporesponsiveness. The Journal of Immunology, 182, 1901-1911.
    1. Belkaid, Y. & Harrison, O.J. (2017) Homeostatic Immunity and the Microbiota. Immunity, 46, 562-576.

LinkOut - more resources